Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non‒Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial
- Resource Type
- Article
- Source
- Journal of Thoracic Oncology; 20240101, Issue: Preprints
- Subject
- Language
- ISSN
- 15560864; 15561380